Catherine London, who has more than two decades of experience in the pharma and healthcare sectors, has joined biOasis Technologies as executive VP-corporate affairs and IR. She reports to CEO Mark Day.
|
|
Catherine LondonMost recently, London did a two-year stint as corporate communications chief at Purdue Pharma, maker of Oxycontin.
Earlier, she held corporate and product PR positions at Alexion Pharmaceuticals and Boehringer Ingelheim and worked at communications firms Chandler Chicco and Ruder Finn.
At biOasis, London assumes a newly created post in charge of external communications, visibility, brand-building and financial communications.
CEO Day praised London as a “forward-thinking communications leader and collaborative relationship builder.”
biOasis, which is based in Vancouver, has developed treatments for neurological diseases such as brain cancers, neurodegenerative and metabolic diseases.
Charlie Chapman, a policy advisor to Health & Human Services Secretary Robert Kennedy Jr., has joined BGR’s health & life sciences practice.
The future of DTC should foster understanding and trust, as well as improving clinical conversations.
Healing the Sick Care System: Why People Matter, a new book from FINN Partners chair global health and purpose Gil Bashe, says that the current healthcare system is not broken because it lacks innovation, talent or investment, but because it has lost sight of the people it exists to serve.
